TGFB1 and nephrocalcinosis: Therefore, we explored the capacity of a delayed anti-TGFβ IgG treatment to improve GFR in mice with nephrocalcinosis by initiating anti-TGFβ or control IgG1 therapy from day 7, a time point when some tubular atrophy had already established (Figure S2 in Supplementary Material).